MGTX · Meiragtx Holdings PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $293.0K | - | $410.0K | $3.69M | - | - | $10.91M | $282.0K | $697.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $31.98M | - | $32.53M | $33.49M | $32.78M | - | $26.24M | $34.93M | $34.32M | - |
| SG&A | $8.93M | - | $13.62M | $12.31M | $9.36M | - | $12.72M | $11.26M | $13.15M | - |
| Total Operating Expenses | $41.11M | - | $46.46M | $48.48M | $43.52M | - | $50.95M | $46.19M | $47.47M | - |
| D&A | $3.01M | - | $3.26M | $3.19M | $3.08M | - | - | - | $3.27M | - |
| Operating Income | ($40.82M) | - | ($46.05M) | ($44.79M) | ($41.60M) | - | ($40.04M) | ($45.91M) | ($46.77M) | - |
| Interest Expense | $2.85M | - | $3.06M | $3.03M | $3.04M | - | $3.36M | $3.25M | $3.25M | - |
| Income Tax | $0 | - | - | - | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($46.31M) | - | ($50.51M) | ($38.80M) | ($39.98M) | - | ($39.33M) | ($48.62M) | ($20.44M) | - |
| EPS - Basic | ($0.57) | - | ($0.62) | ($0.48) | ($0.51) | - | ($0.55) | ($0.76) | ($0.32) | - |
| EPS - Diluted | ($0.57) | - | ($0.62) | ($0.48) | ($0.51) | - | ($0.55) | ($0.76) | ($0.32) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $71.54M | $65.93M | $14.84M | $32.17M | $66.52M | $103.66M | $122.87M | $99.97M | $119.21M | $129.57M |
| Accounts Receivable | $3.26M | $3.00M | $2.81M | $2.32M | $734.0K | $707.0K | $3.28M | $1.63M | $10.91M | $10.14M |
| Inventory | - | - | - | $314.0K | $607.0K | $385.0K | - | - | - | - |
| Accounts Payable | $16.66M | $10.07M | $21.54M | $25.59M | $20.29M | $23.59M | $29.50M | $21.40M | $21.22M | $16.04M |
| Current Assets | $96.20M | $91.76M | $34.17M | $47.08M | $79.89M | $123.52M | $139.05M | $110.77M | $149.30M | $159.62M |
| Total Assets | $244.66M | $244.43M | $189.47M | $198.72M | $224.01M | $269.75M | $299.49M | $266.65M | $309.24M | $326.74M |
| Current Liabilities | $176.13M | $122.56M | $152.92M | $53.44M | $52.37M | $60.78M | $59.42M | $47.01M | $47.54M | $67.08M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $302.79M | $250.22M | $230.03M | $195.76M | $190.91M | $201.92M | $203.75M | $186.61M | $187.50M | $188.57M |
| Stockholders' Equity | ($58.13M) | ($5.79M) | ($40.56M) | $2.96M | $33.10M | $67.83M | $95.74M | $80.04M | $121.73M | $138.18M |
| Retained Earnings | ($862.54M) | ($816.22M) | ($831.31M) | ($780.80M) | ($742.00M) | ($702.02M) | ($662.62M) | ($623.29M) | ($574.67M) | ($554.23M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.81M | - | - | - | ($36.83M) | - | - | - | ($36.74M) | - |
| Investing Cash Flow | ($2.26M) | - | - | - | ($1.71M) | - | - | - | $27.34M | - |
| Financing Cash Flow | ($10.11M) | - | - | - | $1.71M | - | - | - | ($1.27M) | - |
| CapEx | $2.01M | - | - | - | $1.71M | - | - | - | $1.68M | - |
| Free Cash Flow | $15.80M | - | - | - | ($38.54M) | - | - | - | ($38.42M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -13930.7% | - | -11232.0% | -1213.6% | - | - | -367.0% | -16279.8% | -6710.5% | - |
| EBITDA margin | -12904.1% | - | -10437.1% | -1127.1% | - | - | - | - | -6240.6% | - |
| Net margin | -15806.5% | - | -12320.2% | -1051.1% | - | - | -360.5% | -17241.1% | -2932.9% | - |
| Free cash flow margin | 5393.2% | - | - | - | - | - | - | - | -5512.1% | - |
| FCF / Net income | -0.34 | - | - | - | 0.96 | - | - | - | 1.88 | - |
| R&D / Revenue | 10916.0% | - | 7934.6% | 907.5% | - | - | 240.5% | 12387.9% | 4924.2% | - |
| SG&A / Revenue | 3047.1% | - | 3321.0% | 333.6% | - | - | 116.6% | 3991.8% | 1886.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -18.9% | - | -26.7% | -19.5% | -17.8% | - | -13.1% | -18.2% | -6.6% | - |
| Return on equity | 79.7% | - | 124.5% | -1310.6% | -120.8% | - | -41.1% | -60.7% | -16.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.55 | 0.75 | 0.22 | 0.88 | 1.53 | 2.03 | 2.34 | 2.36 | 3.14 | 2.38 |
| Quick ratio | 0.55 | 0.75 | 0.22 | 0.88 | 1.51 | 2.03 | 2.34 | 2.36 | 3.14 | 2.38 |
| Cash ratio | 0.41 | 0.54 | 0.10 | 0.60 | 1.27 | 1.71 | 2.07 | 2.13 | 2.51 | 1.93 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -14.3x | - | -15.0x | -14.8x | -13.7x | - | -11.9x | -14.1x | -14.4x | - |
| Equity multiplier | -4.21 | -42.19 | -4.67 | 67.13 | 6.77 | 3.98 | 3.13 | 3.33 | 2.54 | 2.36 |
| Liabilities / Assets | 1.24 | 1.02 | 1.21 | 0.99 | 0.85 | 0.75 | 0.68 | 0.70 | 0.61 | 0.58 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.02 | - | - | 0.04 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 4065d | - | 2500d | 229d | - | - | 110d | 2107d | 5716d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 177.5x | 16.2x | - | 3.1x | 3.4x | 3.2x | - |
| P / S | 2403.0x | - | 1624.9x | 142.4x | - | - | 27.4x | 961.1x | 557.9x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | -96.2% | 1208.9% | - | - | 113.8% | -92.0% | -79.1% | - |
| Revenue CAGR (3y) | -55.5% | - | -56.0% | -30.0% | - | - | 16.2% | -61.9% | -46.7% | - |
| Revenue CAGR (5y) | -42.3% | - | -39.6% | 8.3% | - | - | 24.9% | -32.3% | -2.3% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 1.9% | - | -15.0% | 2.4% | 11.1% | - | -22.2% | -59.5% | -47.3% | - |
| Net income growth (YoY) | -15.8% | - | -28.4% | 20.2% | -95.6% | - | 11.2% | -64.4% | 32.7% | - |
| EPS growth (YoY) | -11.8% | - | -12.7% | 36.8% | -59.4% | - | 25.7% | -43.4% | 48.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | -0.3% | - | - | - | 16.5% | - |
| FCF CAGR (5y) | 28.1% | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | -96.3% | -72.8% | -50.9% | 4.2% | -35.2% | 34.9% | 17.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$81.39M totalLicense$74.99M · 92.1%
Related Party Service Revenue$6.40M · 7.9%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing MeiraGTx Holdings plc against the 5 most active filers in the same SIC group.